Article
Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.
Medical oncology (Northwood, London, England) - 10 Sept 2026
Chatterjee Srijita, Arya Swati, Sharma Nidhi, Grover Madhuri, Yadav Divya, Parveen Hiba
Abstract excerpt
One of the most commonly mutated oncogenes is Kirsten rat sarcoma viral oncogene homolog (KRAS, which is found in nearly all pancreatic ductal adenocarcinomas (PDAC), is commonly found in colorectal cancers (CRC), and is found in significant numbers in non-small-cell lung cancers (NSCLC). For most of its history, KRAS has been regarded as "undruggable." Still, with recent developments in covalent inhibitors...
Read the complete abstract on PubMedTopics
- Humans
- Proto-Oncogene Proteins p21(ras)
- Mutation
- Neoplasms
- Antineoplastic Agents
- Molecular Targeted Therapy